📰 Evidence Development News
Page 6 - Evidence Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evidence Development. Real-time updates on events, politics, business and more.
March 9, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...
March 1, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...
March 1, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...
February 23, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
February 17, 2022
NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”)...
February 15, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...
February 15, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...
February 8, 2022
The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating
February 1, 2022
There may be ways to introduce price control under federal drug programmes by stealth in the absence of state price negotiations.
January 31, 2022
There may be ways to introduce price control under federal drug programmes by stealth in the absence of state price negotiations.